91 FR 49406 · published 2026-08-04
· effective 2026-07-31
· Commerce Department, Industry and Security Bureau
Mirrored from the Federal Register (retrieved 2026-08-08) —
the official copy is at federalregister.gov
(their site may ask for human verification).
This notice revises the tariff rate on patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United Kingdom from 10 percent to zero percent in accordance with Proclamation 11020 "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States."
[Federal Register Volume 91, Number 148 (Tuesday, August 4, 2026)]
[Notices]
[Pages 49406-49407]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-15799]
DEPARTMENT OF COMMERCE
Bureau of Industry and Security
[Docket No. 260731-0181]
XRIN 0694-XC159
Notice of Reduction of Tariffs on Patented Pharmaceuticals and
Pharmaceutical Ingredients for Products of the United Kingdom
Implemented by Presidential Proclamation 11020
AGENCY: Bureau of Industry and Security, Office of Strategic Industries
and Economic Security, U.S. Department of Commerce.
ACTION: Notice.
SUMMARY: This notice revises the tariff rate on patented
pharmaceuticals and associated pharmaceutical ingredients that are
products of the United Kingdom from 10 percent to zero percent in
accordance with Proclamation 11020 ``Adjusting Imports of
Pharmaceuticals and Pharmaceutical Ingredients Into the United
States.''
DATES: The duties set out in this notice are effective with respect to
certain products that are entered for consumption, or withdrawn from
warehouse for consumption, on or after 12:01 a.m. Eastern Time on July
31, 2026.
SUPPLEMENTARY INFORMATION:
Background
On April 2, 2026, The President issued Proclamation 11020
``Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients
Into the United States,'' (Presidential Proclamation) on April 2, 2026,
to adjust imports of patented pharmaceuticals and associated
pharmaceutical ingredients, (Proclamation 11020 of April 2, 2026) (91
FR 18183).
The Presidential Proclamation directed the Secretary to publish a
Federal Register Notice indicating that the tariff rate on patented
pharmaceuticals and associated pharmaceutical ingredients that are
products of the United Kingdom will be reduced to zero to the extent
required by any future agreement between the United States and the
United Kingdom on pharmaceutical pricing. On April 2, 2026, the United
States and the United Kingdom announced the successful conclusion of
the pharmaceutical pricing agreement as outlined in the ``Arrangement
Between the Government of the United States of America and the
Government of the United Kingdom of Great Britain and Northern Ireland
on Pharmaceutical Pricing'' https://ustr.gov/sites/default/files/files/Press/Releases/2026/U.S.-UK%20Pharma%20Pricing%20Arrangement%20-%204.2.2026.pdf. Furthermore, the requirements of section IV.1.a of the
Arrangement are currently being met. Therefore, the tariff rate for
patented pharmaceuticals and associated pharmaceutical ingredients that
are products of the United Kingdom is now zero.
Modifications to the Harmonized Tariff Schedule of the United States
Effective with respect to goods entered for consumption, or
withdrawn for consumption, on or after 12:01 a.m. eastern time on July
31, 2026, heading 9903.04.63 of the Harmonized Tariff
Schedule of the United States is amended by deleting ``+10%'' in each
place that it appears and inserting ``+0%'' in lieu thereof.
Jessica Curyto,
Deputy Assistant Secretary for Technology Security.
[FR Doc. 2026-15799 Filed 7-31-26; 4:15 pm]
BILLING CODE 3510-33-P
Public-domain US Government work, mirrored verbatim by the Trimtab US Trade Ledger for citation stability. All tariff paper →